Want to see UTHR full AI Analyst Report?
United Therapeutics (UTHR) Income Statement
United Therapeutics Income Statement
Last quarter (Q2 2026), United Therapeutics's total revenue was $783.30M, a decrease of 1.92% from the same quarter last year. In Q2, United Therapeutics's net income was $333.00M. See United Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 3.18B | $ 2.88B | $ 2.33B | $ 1.94B | $ 1.69B | |
| $ 2.80B | $ 2.57B | $ 2.07B | $ 1.79B | $ 1.56B | |
| $ 1.28B | $ 1.19B | $ 885.10M | $ 809.90M | $ 1.01B | |
| Depreciation and Amortization | $ 85.60M | $ 72.50M | $ 53.20M | $ 51.30M | $ 49.90M |
| $ 1.82B | $ 1.65B | $ 1.39B | $ 1.04B | $ 736.80M | |
| $ 1.52B | $ 1.38B | $ 1.18B | $ 979.70M | $ 555.90M | |
| $ 196.70M | $ 162.00M | $ 89.40M | $ -29.10M | $ 38.00M | |
| $ 1.71B | $ 1.54B | $ 1.27B | $ 950.60M | $ 593.90M | |
| $ 1.33B | $ 1.20B | $ 984.80M | $ 727.30M | $ 475.80M | |
| Per Share Metrics | |||||
| Basic EPS | $ 30.13 | $ 26.44 | $ 21.04 | $ 15.98 | $ 10.60 |
| Diluted EPS | $ 27.86 | $ 24.64 | $ 19.81 | $ 15.00 | $ 10.06 |
| Weighted Average Shares Outstanding | 44.30M | 45.20M | 46.80M | 45.50M | 44.90M |
| Weighted Average Shares Outstanding (Diluted) | 47.90M | 48.50M | 49.70M | 48.50M | 47.30M |
Currency in USD
